All-trans Retinoic Acid (ATRA) Differentiates Acute Promyelocytic Leukemia Cells Independently of P-Glycoprotein (P-gp) Related Multidrug Resistance

References

• Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retin-oic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Chen Z. X., Xue Y. Q., Zhang R., Tao R. F., Xia X. M., Li C., Wang W., Zu W. Y., Yao X. Z., Ling B. J. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr., Frankel S. R., Miller W. H., Jr., Sheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreef M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M. S., Dmitrovski E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N. Engl. J. Med. 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M., Ballarini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Ohno R., Yoshida H., Fukutani H., Naoe T, Ohshima T., Kyo T., Endoh N., Fujimoto T., Kobayashi T., Hiraoka A., Mizoguchi H., Kodera Y., Suzuki H., Hirano M., Aki-Yama H., Aoki N., Shindo H., Yokomaku S. And the Leukemia Study Group of the Ministry of Health and Welfare 1993 Multi-institutional study of all-trans retinoic acid as differentiation therapy of refractory acute promyelocytic leukemia. Leukemia, 7: 1722–1727
   PubMed Web of Science ®Google Scholar
• Takeshita A., Sakamaki H., Miyawaki S., Kobayashi T., Kuriyama K., Yamada O., Oh H., Takenaka T., Asou N., Ohno R. And Japan adult leukemia study group 1995 Significant reduction of medical costs by differentiation therapy with all trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. Cancer, 76: 602–608
   PubMed Web of Science ®Google Scholar
• Kanamaru A., Takemoto Y., Tanimoto M., Murakami H., Asou N., Kobayashi T., Kuriyama K., Oh H., Saito K., Matsuda S., Minato K., Ueda T., Ohno R. And the Japan Adult Leukemia Study Group 1995 All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood, 85: 1202–1206
   PubMed Web of Science ®Google Scholar
• Asou N., Adachi K., Tamura J., Kanamaru S., Kageyama S., Hiraoka A., Omoto E., Akiyama H., Tsubaki K., Saito K., Kuriyama K., Oh H., Kitano K., Miyawaki S., Takeyama K., Yamada O., Nishikawa K., Takahashi M., Matsuda S., Ohtake S., Suzushima H., Emi N., Ohno R. For the Japan Adult Leukemia Study Group 1998 Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J. Clin. Oncol., 16: 78–85
   PubMed Web of Science ®Google Scholar
• Yoshida H., Naoe T., Fukitani H., Kiyoi H., Kubo K., Ohno R. Analysis of the joining sequences of the t(15; 17) translocation in human acute promyelocytic leukemia: Sequence non-specific recombination between the PML and RARA genes within identical short stretches. Genes Chrom. Cancer 1995; 12: 37–44
   PubMed Web of Science ®Google Scholar
• Degos L., Dombret H., Chomienne C., Daniel M., Miclea J. M., Chastag C., Castaigne S., Fenaux P. All-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid resistance in patients with acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 1993; 82: 1949–1953
   PubMed Web of Science ®Google Scholar
• Degos L., Dombret H., Chomienne C., Daniel M., Miclea J. M., Chastag C., Castaigne S., Fenaux P. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643–2653
   PubMed Web of Science ®Google Scholar
• Roberts A. B., Lamb L. C., Sporn M. B. Metabolism of all-trans retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy-to 4-keto retinoic acid. Arch. Biochem. Biophys. 1980; 199: 374–383
   PubMed Web of Science ®Google Scholar
• Muindi J. R.F., Frankel S. R., Miller W. H., Jr., Jakubowski A., Scheinberg D. A., Young C. W., Dmitrowski E., Wallel R. P. Continuous treatment with all-trans retinoic acid causes a progressive decrease in plasma concentrations: Implications for relapse and “resistance” in acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Robertson K. A., Emami B., Collins S. J. Retinic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992; 80: 1885–1889
   PubMed Web of Science ®Google Scholar
• Dermine S., Grignani F., Clerici M., Nervi C., Sozzi G., Talamo G. P., Marcheshi E., Formelli F., Parmiani G., Pelicci P. G., Gambacorti-Passerrini C. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RARα protein. Blood 1993; 82: 1573–1577
   PubMed Web of Science ®Google Scholar
• Adamson P. C., Boylan J. F., Balis F. M., Murphy R. F., Godwin K. A., Gudas L. J., Poplack D. G. Time course of induction of metabolism of all-trans retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res. 1993; 53: 472–476
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr., de The H., Wang Z. Y., Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Cornic M., Delva L., Castaigne S., Lefebvre P., Balitrand N., Degos L., Chomienne C. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994; 8: 16–19; 1994, Suppl
   PubMed Web of Science ®Google Scholar
• Rosennauer A., Raelson J. V., Nervi C., Eydoux P., De Blasio A., Miller W. H., Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearrenged and wild-type retinoid receptors in retinoid-resislant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671–2681
   PubMed Web of Science ®Google Scholar
• Chen Chin C., Ueda J.K., Clark D. P., Pastan I., Gottesman M. M., Robinson I. B. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–389
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Kizaki M., Ueno H., Yamazoe Y., Shimada M., Takeyama N., Muto Å., Matsushita H., Nakajima H., Morikawa M., Koeffler H. P., Ikeda Y. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996; 87: 725–733
   PubMed Web of Science ®Google Scholar
• Ohno R., Ohnishi K., Takeshita A., Tanimoto M., Murakami H., Kanamaru A., Asou N., Kobayashi T., Kuri-Yama K., Ohmoto E., Sakamaki H., Tsubaki K., Hiraoka A., Yamada O., Oh H., Furusawa S., Matsuda S., Naoe T. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 1994; 8: 64–69, suppl
   Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T, Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Paietta E., Andersen J., Racevkis J., Gallagher R., Bennett J., Yunis J., Cassileth P., Wiernik PH. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia 1994; 8: 968–973
   PubMed Web of Science ®Google Scholar
• Drach D., Zhao S., Drach J., Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukemia. Br. J. Haematol. 1995; 90: 369–374
   PubMed Web of Science ®Google Scholar
• Takeshita A., Shinjo K., Ohnishi K., Ohno R. New flow cytometric method for detection of minimally expressed multidruf resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavi-din-RED670 conjugate. Jpn. J. Cancer Res. 1995; 86: 607–615
   PubMedGoogle Scholar
• Takeshita A., Shinjo K., Ohnishi K., Ohno R. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukemia cells. Br. J. Haematol 1996; 93: 18–21
   PubMed Web of Science ®Google Scholar
• Kagechika H., Kawaguchi E., Hashimoto Y., Himi T, Shudo K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J. Med. Chem. 1988; 31: 2182–2192
   PubMed Web of Science ®Google Scholar
• Hashimoto Y., Kagechika H., Kawachi E., Fukazawa H., Saito G., Shudo K. Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL60 and NB4. J. Cancer Res. Clin. Oncol 1995; 121: 696–698
   PubMed Web of Science ®Google Scholar
• Kahan J. The fluorescence properties if vitamin A and their changes during photodecomposition. Acta. Chem. Scand. 1967; 21: 2515–2524
   PubMedGoogle Scholar
• Takeshita A., Shinjo K., Naito K., Fujisawa S., Shigeno K., Ohnishi K., Naoe T., Ohno R. No Role of P-glycoprotein (P-gp) to all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukemia (APL) cells: analysis of P-gp and intra-cellular concentration of ATRA. Blood 1998; 92: 597a, Suppl 1 abstr
   Web of Science ®Google Scholar
• Takeshita A., Shinjo K., Naito K., Ohnishi K., Sugimoto Y., Yamakawa Y., Tanimoto M., Kitamura K., Naoe T., Ohno R. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukemia cells: analysis of intracellular concentration of ATRA. Br. J. Haematol. 2000; 108: 90–92
   PubMed Web of Science ®Google Scholar
• Kitamura K., Kiyoi H., Yoshida H., Saito H., Ohno R., Naoe T. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia. Leukemia 1997; 11: 1950–1956
   PubMed Web of Science ®Google Scholar
• Su G. M.I., Davey M. W., Davey R. A., Kidman A. Development of extended multidrug resistance in HL60 promyelocytic leukemia cells. Br. J. Haematol. 1994; 88: 566–574
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposal for the classification of the acute leukemias. Br. J. Haematol. 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. A variant form of hypergranular promyelocytic leukemia (M3). Ann. Intern. Med. 1980; 92: 261–262
   PubMed Web of Science ®Google Scholar